All cancer entities, except for: Cholangiocarcinoma, Glioblastoma,Acute leukemias, Basalioma, Melanoma without intended systemic treatment
Conditions
Interventions
Group 1: Patients aged =65 years with newly diagnosed cancer or before receiving a new treatment line.
This study includes both routine procedures and study-specific procedures for patients who meet
Sponsors
Institut für Geriatrische Forschung der Universitätsklinik Ulm, AGAPLESION Bethesda Klinik Ulm
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients aged 65 years and older with a G8 score of =14 points, indicating the need for a CGA. OR Patients aged 70 years or older, regardless of their G8 score, as they are considered at a higher risk due to age. Patients with a newly diagnosed cancer who are awaiting the start of treatment (e.g., radiothera-py, surgery, systemic therapy such as chemotherapy, targeted therapy, immunotherapy, or endo-crine therapy), or those who are about to begin a new treatment line. Patients awaiting a MDT meeting for treatment decisions. All types of cancer are eligible for inclusion, except for those listed in the exclusion criteria. Patients must be able to provide informed consent during their initial geriatric consultation.
Exclusion criteria
Exclusion criteria: - Unable to understand the informed consent due to clinically overt dementia and/or language barriers. - Patients will be excluded from the study if they have the following types of cancer: - Cholangiocarcinoma - Glioblastoma - Acute leukemia - Basal cell carcinoma - Melanomas without systemic treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimation of willingness to participate with an accuracy of 7.5%. | — |
Secondary
| Measure | Time frame |
|---|---|
| a. Presence of a completed CGA before the first tumour board meeting (percentage, purely descriptive) b. Qualitative assessment of the integration of the CGA into the tumour board c. Time required to complete a CGA d. Follow-up after 3 months: Assessment of quality of life and functional status using ELFI 2.0 e. Analysis of polypharmacy and proposed medication changes | — |
Countries
Germany
Contacts
Public ContactMichael Denkinger
Institut für Geriatrische Forschung der Universitätsklinik Ulm, AGAPLESION Bethesda Klinik Ulm
Outcome results
None listed